Skip NavigationSkip to Content
Return Return to Search Results

Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme

  1. Author:
    Krauss, J.
    Arndt, M. A. E.
    Vu, B. K.
    Newton, D. L.
    Rybak, S. M.

  2. Author Address

    Natl Canc Inst, SAIC, Frederick, MD USA. Natl Canc Inst, Dev Therapeut Program, Frederick, MD 21702 USA Krauss, J, Univ Essen Gesamthsch, Dept Internal Med Canc Res, D-45122 Essen, Germany
    1. Year: 2005
    2. Date: MAR
  2. Journal: British Journal of Haematology
    1. 128
    2. 5
    3. Pages: 602-609
  4. Type of Article: Article
  1. Abstract:

    We report on the generation and functional characterization of a humanized immunoenzyme comprising a stable humanized single chain Fv (scFv) with grafted specificity of the anti-CD22 murine monoclonal antibody RFB4 and the human ribonuclease angiogenin (ANG). The fusion protein produced from transiently transfected mammalian Chinese hamster ovary cells could easily be purified to homogeneity, retained full ribonucleolytic activity, and efficiently killed CD22(+) tumour cells with an IC50 of 56 nmol/l. In contrast, incubation of tumour cells with either ANG or scFv alone did not result in any cytotoxicity. Potent receptor-mediated killing of target cells, expected lack of extracellular toxicity, predictable low immunogenic potential, and ease of production, suggest that this novel immunoenzyme has potential for the immunotherapy of CD22(+) malignancies

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1111/j.1365-2141.2005.05356.x
  3. View record in Web of Science®
  4. WOS: 000227178300003

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel